Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 11/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22721406 | 1.00 | ROCK2 (0.47) | ROCK2DNM1MITFALDH1A1LMNA | |
| SCHEMBL22721410 | 0.85 | ROCK2 (0.47) | ROCK2DNM1MITFALDH1A1LMNA | |
| SCHEMBL22721408 | 0.85 | ROCK2 (0.47) | ROCK2DNM1MITFALDH1A1LMNA | |
| SCHEMBL22743865 | 0.77 | CD274 (0.47) | MITFALDH1A1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL18322510 | 0.74 | ROCK2 (0.46) | ROCK2DNM1ALDH1A1NPSR1CD274 | |
| SCHEMBL20297332 | 0.74 | ROCK2 (0.46) | ROCK2DNM1ALDH1A1NPSR1CD274 | |
| SCHEMBL26324062 | 0.74 | MAOA (0.45) | — | |
| SCHEMBL22721455 | 0.73 | KMT2A (0.50) | ROCK2DNM1ALDH1A1SMN1; SMN2CD274 | |
| SCHEMBL22721453 | 0.73 | KMT2A (0.50) | ROCK2DNM1ALDH1A1SMN1; SMN2CD274 | |
| SCHEMBL844114 | 0.72 | MAOA (0.47) | ALDH1A1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174289-B | Benzotriazole derivatives | ＵＢＥ株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| CN-114174289-A | Benzotriazole derivatives | 宇部兴产株式会社 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020241853-A1 | BENZOTRIAZOLE DERIVATIVE | 宇部興産株式会社 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | KEAP1, NFE2L2, BACH1 | ROCK2 3375/4885DNM1 3319/4885MITF 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.